Asos

EQS-News: Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies

Retrieved on: 
Wednesday, April 10, 2024
CE, Asos, Drug discovery, Central nervous system, Patient, Ophthalmology, RNA, Research, CBO, Protein, Drug development, Medical device

EQS-News: Secarna Pharmaceuticals GmbH & Co. KG

Key Points: 
  • EQS-News: Secarna Pharmaceuticals GmbH & Co. KG
    The issuer is solely responsible for the content of this announcement.
  • Dallas, TX, USA and Martinsried, Germany, March 20, 2024 – Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, and Secarna Pharmaceuticals GmbH & Co. KG, a leading independent European antisense drug discovery and development company, today announced a research collaboration for the development of long-acting implants that deliver antisense oligonucleotides (ASOs).
  • “Collaborating with Secarna allows us to develop an innovative implant that has the potential to significantly change the way disease-modifying ASO therapies are administered,” said Cyonna Holmes, Global Business Strategy Leader for Ophthalmology and RNA at Celanese.
  • “We are looking forward to partnering with Celanese to combine our industry-leading ASO platform with their VitalDose® drug delivery technology,” said Konstantin Petropoulos, CBO of Secarna Pharmaceuticals.

Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies

Retrieved on: 
Wednesday, March 20, 2024
Research, General Health, Pharmaceutical, Oncology, Data Management, Technology, Infectious Diseases, Science, Chemicals, Plastics, Biotechnology, Manufacturing, Health, CE, Asos, Drug discovery, Central nervous system, Patient, Corporation, Ophthalmology, RNA, CBO, Protein, Drug development, Medical device

Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, and Secarna Pharmaceuticals GmbH & Co. KG, a leading independent European antisense drug discovery and development company, today announced a research collaboration for the development of long-acting implants that deliver antisense oligonucleotides (ASOs).

Key Points: 
  • Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, and Secarna Pharmaceuticals GmbH & Co. KG, a leading independent European antisense drug discovery and development company, today announced a research collaboration for the development of long-acting implants that deliver antisense oligonucleotides (ASOs).
  • “Collaborating with Secarna allows us to develop an innovative implant that has the potential to significantly change the way disease-modifying ASO therapies are administered,” said Cyonna Holmes, global business strategy leader for Ophthalmology and RNA at Celanese.
  • With several high value and innovative programs, Secarna has validated its platform in various indications such as cardiometabolic, immune-oncology, fibrotic/inflammatory diseases and the central nervous system.
  • “We are looking forward to partnering with Celanese to combine our industry-leading ASO platform with their VitalDose® drug delivery technology,” said Konstantin Petropoulos, CBO of Secarna Pharmaceuticals.

isolved Earns Top Placement in Core HR Plus Talent Management in ISG Provider Lens™

Retrieved on: 
Wednesday, March 13, 2024
Cloud, LMS, HR, Face, Asos, NLP, Artificial intelligence, Small, ISG, AI, Software, LAS, IPPA, Investment, HCM, Human resource management, Sales

LAS VEGAS, March 13, 2024 /PRNewswire/ -- IPPA -- On the heels of isolved®'s release of its fourth-annual human resource (HR) leaders research study, the company has been named a Leader in an analyst evaluation examining the top HR systems. ISG, a leading global technology and advisory firmed has released its Provider Lens™ evaluation for Human Capital Management (HCM) Platforms and has recognized isolved as a Leader in Core HR Technology Plus Talent Management for the Small and Midmarket. The staunchly independent firm evaluated solution providers that offer products for automating and enabling core HR functions including benefits administration, payroll and workforce management.

Key Points: 
  • ISG, a leading global technology and advisory firmed has released its Provider Lens™ evaluation for Human Capital Management (HCM) Platforms and has recognized isolved as a Leader in Core HR Technology Plus Talent Management for the Small and Midmarket.
  • The staunchly independent firm evaluated solution providers that offer products for automating and enabling core HR functions including benefits administration, payroll and workforce management.
  • "In the landscape of HR technology, where adaptability is paramount, isolved stands out as a Leader in Core HR Technology," remarked Stacey Cadison, lead author on the ISG Provider Lens for HCM.
  • "We're thrilled ISG recognized both in its latest evaluation of HCM vendors where isolved is positioned in the top spot overall.

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress

Retrieved on: 
Wednesday, March 6, 2024
Therapy, Distribution, Messenger, MicroRNA, Adenocarcinoma, Asos, Vaccine, RNA, Pharmacokinetics, Dicarboxylic acid, Patient, Oligonucleotide, Congress, IND, RNA interference, Metastasis, Cancer

BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that its Chief Scientific Officer, Zdravka Medarova, Ph.D., will present at this year’s RNA Leaders Europe Congress scheduled to take place March 12-14 in Basel, Switzerland.

Key Points: 
  • BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that its Chief Scientific Officer, Zdravka Medarova, Ph.D., will present at this year’s RNA Leaders Europe Congress scheduled to take place March 12-14 in Basel, Switzerland.
  • The conference is focused on the development of mRNA, RNAi, ASOs, oligonucleotides, vaccines, microRNAs, genome editing, wider nucleic acids and RNA targets.
  • It is expected that delegates from leading companies in these areas will be in attendance.
  • The presentation will also describe key activities completed in support of TransCode’s planned Phase 1/2 trial for which it plans to file an IND in March 2024.

QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia

Retrieved on: 
Monday, March 4, 2024
Alzheimer's disease, ALS, Real-time, TAR, Synapse, Pathology, Neuron, Neurodegenerative disease, Asos, SNARE, Conference, Frontotemporal dementia, FTD, IPSC, RNA, Phenotype, Patient, Spinal cord, Brain cell, DSM-IV codes, Brain

CAMBRIDGE, Mass., March 4, 2024 /PRNewswire/ -- QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that will alter the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases, today announced preclinical data that showed the company's UNC13A splice-switching antisense oligonucleotides (ASOs) modulate UNC13A splicing and restore normal synaptic activities in ALS and FTD. QurAlis' ASOs prevented cryptic exon inclusion in UNC13A transcripts, increased UNC13A protein levels, and normalized localization of UNC13A protein at the synapse.

Key Points: 
  • QurAlis' ASOs prevented cryptic exon inclusion in UNC13A transcripts, increased UNC13A protein levels, and normalized localization of UNC13A protein at the synapse.
  • A defining feature of both sporadic and familial disease is the cytoplasmic mis-localization of TAR DNA Binding Protein-43 (TDP-43).
  • "QurAlis has identified ASOs that modulate UNC13A splicing and restore normal synaptic activities.
  • QurAlis' ASOs restored all or some aspects of SNARE complex assembly and synaptic vesicle fusion and release.

Lee Announces Global Collaboration With Legendary Artist Jean-Michel Basquiat

Retrieved on: 
Tuesday, February 6, 2024
Textiles, Women, Arts, Museums, Entertainment, Men, Manufacturing, Fashion, Consumer, Retail, Licensing (Entertainment), Multimedia, Life, Lee, Human, Estate, Personality, Asos, Nordstrom, Marketing, Collection, Poetry, Zalando, Woman, Poverty, Urban Outfitters, Culture, Jewellery

Today, Lee® announces the launch of a collection featuring the work of artist Jean-Michel Basquiat.

Key Points: 
  • Today, Lee® announces the launch of a collection featuring the work of artist Jean-Michel Basquiat.
  • View the full release here: https://www.businesswire.com/news/home/20240206762674/en/
    Lee® launches global collaboration with artist Jean-Michel Basquiat that blends legendary denim with groundbreaking art.
  • Similarly, Lee has been influencing the world of denim for 100 years, creating styles like the Lee Rider™ jacket, a true original that’s often copied, but never replicated.
  • “Lee has always celebrated originality, and in our 100 years we’ve been part of American culture, especially the ‘80s around NYC,” said Brigid Stevens, global vice-president of marketing, Lee.

Deliveroo partners with Rokt to expand retail media with non-endemic offers

Retrieved on: 
Monday, January 29, 2024
Asos, Redbubble, Advertising, Partnership, E-commerce, DTC, Travel, Lyft, Machine learning, Marketing, Headspace, Food delivery

Deliveroo has been building its retail media network since launching its advertising platform in 2021, supporting its restaurant partners to reach more customers on the platform.

Key Points: 
  • Deliveroo has been building its retail media network since launching its advertising platform in 2021, supporting its restaurant partners to reach more customers on the platform.
  • This means that advertisers in the Rokt Ads network can now access Deliveroo's audiences, and Deliveroo can provide the most relevant third-party offers to customers on their order confirmation page.
  • "We're absolutely thrilled to welcome Deliveroo to the Rokt family," said Craig Galvin, Chief Revenue Officer at Rokt.
  • Deliveroo is the latest in a series of new partners Rokt has launched with this year, including Redbubble, Asos, Klarna, Lyft, boohoo, Morrisons, and Afterpay.

Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S

Retrieved on: 
Tuesday, January 23, 2024
Patient, Life, Peripheral neuropathy, NMD, CMT, Genetics, Medicine, IND, Food, Journal, Journal of Biological Chemistry, Central nervous system, FDA, Vanda, Investigational New Drug, Atrophy, Neuromuscular disease, Charcot–Marie–Tooth disease, Asos, Gene expression, Prevalence

CMT2S is a rare subtype of Charcot-Marie-Tooth disease (CMT), an inherited peripheral neuropathy for which there is no available treatment.

Key Points: 
  • CMT2S is a rare subtype of Charcot-Marie-Tooth disease (CMT), an inherited peripheral neuropathy for which there is no available treatment.
  • VCA-894A is a novel antisense oligonucleotide (ASO) with a mechanism of action that specifically targets a cryptic splice site variant within immunoglobulin mu-binding protein 2 (IGHMBP2).
  • Truncating and missense mutations in IGHMBP2 cause Charcot-Marie Tooth disease type 2.
  • https://doi.org/10.1016/j.nmd.2021.08.001
    Crooke, S. T., Liang, X. H., Baker, B. F., & Crooke, R. M. (2021).

EQS-News: Northern Data Group appoints Group Chief Financial Officer

Retrieved on: 
Wednesday, January 17, 2024
Cloud, Asos, Audit, KPMG, HM Land Registry, CFO, Taiga, University, New Zealand Institute, Risk, Growth, Ticker, NB2, IPO, HPC, Supercomputer

Elliot Jordan will join the Group’s Executive Committee, bringing extensive finance and capital markets experience

Key Points: 
  • Elliot Jordan will join the Group’s Executive Committee, bringing extensive finance and capital markets experience
    Frankfurt/Main – 15 January 2024 – Northern Data Group (Ticker symbol German stock market: NB2 , ISIN: DE000A0SMU87 ) a leading provider of High-Performance Computing (HPC) infrastructure solutions, today announces a key appointment to its Group Executive Committee of Elliot Jordan as Group Chief Financial Officer.
  • In his role as Group Chief Financial Officer, Elliot will lead Northern Data Group’s financial strategy and support the Group’s wider growth as it drives innovation across the HPC market.
  • Aroosh Thillainathan, Founder and Group Chief Executive Officer, comments: “I’m very pleased to welcome Elliot to Northern Data Group and the Group Executive Committee.
  • Following Aroosh’s vision, Northern Data Group has become a leading provider of High-Performance Computing solutions and is primed to capitalize on the global market opportunity.”

Northern Data Group appoints Group Chief Financial Officer

Retrieved on: 
Monday, January 15, 2024
Cloud, Asos, Audit, KPMG, Executive Committee, HM Land Registry, CFO, Taiga, University, New Zealand Institute, Risk, Growth, Ticker, NB2, IPO, HPC, Sainsbury's, Supercomputer, Management

Elliot Jordan will join the Group's Executive Committee, bringing extensive finance and capital markets experience

Key Points: 
  • Elliot Jordan will join the Group's Executive Committee, bringing extensive finance and capital markets experience
    FRANKFURT, Germany, Jan. 15, 2024 /PRNewswire/ -- Northern Data Group (Ticker symbol German stock market: NB2 , ISIN: DE000A0SMU87 ) ), a leading provider of High-Performance Computing (HPC) infrastructure solutions, today announces a key appointment to its Group Executive Committee of Elliot Jordan as Group Chief Financial Officer.
  • In his role as Group Chief Financial Officer, Elliot will lead Northern Data Group's financial strategy and support the Group's wider growth as it drives innovation across the HPC market.
  • Aroosh Thillainathan, Founder and Group Chief Executive Officer, comments: "I'm very pleased to welcome Elliot to Northern Data Group and the Group Executive Committee.
  • Elliot Jordan, incoming Group Chief Financial Officer, comments: "I am delighted to be joining Northern Data Group and the Group Executive Committee at such a pivotal moment for the business as it seeks to continue its pace of growth and embrace the next stage in its journey.